# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC Filing
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate...
https://www.sec.gov/Archives/edgar/data/1750149/000119312525143738/d77556ds3.htm
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate...